Introduction
Almost 90% of cervical cancer-related deaths occurred in the developing countries, and the highest cervical cancer death rates are in Asia, with an estimated 144,400 deaths occurring in 2012. 1 Invasive cancer accounts for .70% of patients diagnosed with cervical cancer, among which squamous cell carcinoma is the most frequent type. 2, 3 Early-stage cervical squamous cell carcinoma (CSCC) cases have a greater possibility of being cured and are associated with excellent survival rates. 4, 5 Since early detection results in a better prognosis, there is an urgent need to identify more efficient early diagnostic biomarkers and therapeutic targets for CSCC.
The Nemo-like kinase (NLK), originally identified as a vertebrate ortholog of Drosophila nemo, 6 is an evolutionarily conserved serine/threonine protein kinase and belongs to the extracellular signal-regulated kinases/microtubule-associated protein kinases family. 7, 8 NLK was proved to be important for tumor cell proliferation, migration, and apoptosis. [9] [10] [11] [12] [13] Increased NLK expression has been reported in several cancers, [14] [15] [16] [17] and variation in NLK may be associated with the risk of invasive
The histological grades were classified according to the World Health Organization criteria. Written informed consent was obtained from the patients for the purpose of research. The patients with CSCC were followed up for clinical evaluation either in the hospital or by telephone. All patients with CSCC were followed up periodically for survival analysis until death or until the study closing date (December 2016). The median follow-up time was 64 months, with a range of 13-88 months. Overall survival (OS) was defined as the period from the date of surgery until death or to the time of the most recent follow-up, and disease-free survival (DFS) was defined as the time interval in months between completion of therapy and recurrence, respectively. Recurrence was either radiologically or histologically confirmed.
Western blot analysis
Proteins from 15 frozen CSCC and 5 frozen normal cervical tissue samples were extracted by suspending them in RIPA buffer consisting of 1% protease inhibitor mixture. The mixture was centrifuged at 12,000× g for 15 minutes at 4°C, and the supernatant was collected. Protein concentrations were quantified by the bicinchoninic acid protein assay kit, and 30 µg of protein extracts was separated by sodium dodecyl sulfate polyacrylamide gel and transferred to methanolactivated nitrocellulose filter membrane (Bio-Rad Laboratories Inc., Hercules, CA, USA). Membranes were blocked with 5% non-fat dry milk before immunodetection. Primary antibodies, NLK (1:1,000 dilution; Abcam, Cambridge, MA, USA), and β-actin were diluted in the buffer and incubated at 4°C overnight. After standard washing, membranes were incubated with a secondary antibody (horseradish peroxidase conjugated) for 1 hour at room temperature. The experiment was accomplished in triplicate.
immunohistochemistry Paraffin-embedded CSCC specimens were cut into 4 µm sections, and then the slides were blocked with 0.3% hydrogen peroxide at 37°C for 30 minutes. To increase specificity and sensitivity, samples were placed in 10 mmol/L citrate buffer (pH 6.0) in a pressure cooker for 2 minutes. The mouse monoclonal antibody against NLK antibodies (1:100 dilution; Abcam) was added to the sections for overnight at 4°C, followed by incubation with mouse secondary antibody (Zhong Shan Golden Bridge Biological Technology Beijing, China) for 20 minutes at room temperature. The sections were immersed in a solution of 3,3-diaminobenzidine tetrahydrochloride (Dako Denmark A/S, Glostrup, Denmark) and then counterstained with hematoxylin. The negative ones were stained with phosphate-buffered saline instead of primary antibodies.
assessment of immunohistochemical staining
The NLK immunoreactivity was semiquantitatively estimated by combining intensity and percentage of positive tumor cells under the microscope as described earlier. 17 The immunostaining results were optimized and judged by 2 independent senior pathologists according to the following standards. The percentage was classified as follows: 0 (0%), 1 (,5%), 2 (5%-50%), and 3 (.50%). The intensity was also scored as follows: 0 (negative staining), 1 (weak staining), 2 (moderate staining), and 3 (intense staining). The final score of NLK expression, ranging from 0 to 6, was the sum of the percentage of positive cells and the intensity score. Patients with a final score of ,4 were classified as the low expression group and vice versa.
statistical analysis
Student's t-test was used to compare continuous variables, and chi-square test was performed to assess differences in clinicopathological variables. OS and DFS were evaluated using the Kaplan-Meier method, and the differences among the levels of possible prognostic factors were compared by the log-rank test in the univariate analyses. The Cox proportional hazards model was used for the multivariate analysis of the independent prognostic factors for OS and DFS. All analyses were performed using statistical software SPSS 13.0 (SPSS 
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Overexpression of nlK Inc., Chicago, IL, USA), and the findings were considered statistically significant at P,0.05.
Results

Patients' characteristics and nlK protein expression in cscc tissues
The expression of NLK was analyzed using specimens from 130 untreated CSCC patients. The median age of the patients was 43 years (range: (Table 1) .
Western blot analysis was used to assess the different levels of NLK expression in CSCC and normal cervical tissues. In Figure 1 , it is shown that NLK protein expression is significantly elevated in CSCC tissues compared with that in normal cervical tissues (P,0.05).
As shown in Figure 2 , NLK was localized mainly in the nucleus of the tumor cells. Of the CSCC specimens examined, low NLK expression was detected in 59 (45.4%) of 130 patients, whereas high NLK expression was detected in 71 (54.6%) of 130 patients. Elevated NLK expression was observed in 28 (90.3%) CSCC patients with lymph node metastasis ( Figure 2C ).
association of nlK protein expression and clinicopathological features
We analyzed the associations between NLK expression status and a series of clinicopathological characteristics, including age, FIGO stage, histological grade, tumor size, parametrial involvement, depth of stromal involvement, vascular/lymphatic invasion, lymph node metastasis, and recurrence (Table 1) . Elevated NLK expression was significantly associated with higher histological grade (P=0.001), vascular/lymphatic invasion (P=0.010), lymph node metastasis (P=0.012), and recurrence (P=0.022). However, no strong association was observed between NLK and age, 
Univariate and multivariate analyses for the prognosis of patients with cscc
The Kaplan-Meier 5-year survival curves stratified for NLK expression are shown in Figure 3 . Both univariate and multivariate survival analyses were used to evaluate the effects of NLK expression and clinicopathological characteristics on prognosis. For OS ( 
Discussion
In this paper, we found that increased NLK expression was significantly associated with higher histological grade, 
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Overexpression of nlK vascular/lymphatic invasion, lymph node metastasis, and recurrence in CSCCs. In multivariate Cox regression analysis, elevated NLK expression was an independent prognostic factor for both OS and DFS. These findings reveal that NLK may serve a potential function in CSCC progression and may thus be used as a valuable biomarker in predicting prognosis in CSCCs. Subcellular fractionation from COS7 cells and HEK293 cells verifies that ~60%-70% of NLK is localized in the nucleus and 30%-40% is localized in the cytoplasm. 20 NLK was predominantly located in the nucleus of tumor cells in nasopharyngeal carcinoma, hepatocellular carcinoma, glioma, and gallbladder cancer; 10, 14, 15, 17 however, NLK was expressed mainly in the cytoplasm of tumor cells in colorectal cancer. 21 NLK-positive staining was confined mainly to the nucleus and cytoplasm in non-small-cell lung cancer (NSCLC). 22 In our study, we found that NLK was localized mainly in the nucleus of the tumor cells. The abovementioned findings suggested that different cytological localizations of NLK in different tumor types might contribute to different biological mechanisms by various signal pathways.
Evidence shows that NLK can serve as an oncogene or tumor suppressor gene dependent on the organ/cell-type specificity. On one hand, NLK acts as an oncogene, and downregulation of this gene may prevent the progression of cancers. Jung et al 9 showed that silencing of NLK decreases cell growth and positively regulates the expression of cyclinD1, a core component of cell cycle regulation in hepatocellular carcinoma cells: Hep3B and SNU-423. Furthermore, low NLK expression decreased significantly the proliferation and migration abilities of GBC-SD and SGC-996 cells in gallbladder carcinoma. 10 On the other 23 In human colon cancer, overexpression of NLK in DLD-1 human colon cancer cell line induced cell apoptosis and inhibited cell proliferation. 24 Overexpression of NLK prevents proliferation and elicits apoptosis in breast cancer cell MCF-7. 25 In glioblastoma cell U87MG, upregulated NLK increases cell apoptosis. 16 In addition, suppression of NLK expression resulted in significant promotion of proliferation in NSCLC cells by facilitating S-phase and mitotic entry, and the activity of β-catenin/ TCF in A549 cells was remarkably enhanced. 26 Our results indicated that NLK played as oncogene; however, we still need to conduct cytological experiments to further verify that NLK gene functions as carcinogenic factor or suppressor in cervical cancer cells.
NLK has been demonstrated to correlate with histological grade, advanced stage, and lymph node metastasis. 14, 15, 17, 21 Similarly, our study suggests that tumors with high NLK expression had greater invasive potential including vascular/ lymphatic invasion. NLK overexpression was also observed in high-invasive regions such as metastatic lymph node. As regards NSCLC, NLK has been found to be inversely correlated with NSCLC histological differentiation, clinical stage, lymph node status, and Ki-67. 26 Besides, NLK expression was reported to be inversely correlated with glioma grade. 16 These different results may attribute to different cytological functions.
Furthermore, high NLK expression can be a strong predictor of poor prognosis. 14, 15, 17, 21 To date, this report is the first to show in detail an association between clinicopathological variables and the prognostic significance of NLK in CSCCs by using clinical samples. Yet, Lv et al 26 reported that low NLK expression was an independent prognostic factor for NSCLC patients' low survival rate by multivariate analysis. However, Lv et al 27 revealed that lentivirus-mediated knockdown of NLK inhibits small-cell lung cancer growth and metastasis. These suggest that the same gene NLK may function differently in the location of histology and cytology.
Conclusion
NLK is overexpressed in the nucleus of the tumor cells in CSCC, and high NLK expression can be correlated with progression, metastasis, and poor survival. These results suggest that NLK may be a potentially novel biomarker for prediction of CSCC. However, these findings remain to be confirmed by a larger future study.
